Financial Performance - The company's operating revenue for Q3 2024 reached ¥165,706,791.74, representing a 22.85% increase year-over-year[2] - Net profit attributable to shareholders was ¥23,169,965.50, a 3.97% increase compared to the same period last year[2] - The net profit excluding non-recurring gains and losses was ¥22,290,304.47, up 18.93% year-over-year[2] - Total operating revenue for Q3 2024 reached ¥441,007,035.99, an increase of 14.8% compared to ¥384,124,776.46 in the same period last year[13] - Total operating costs amounted to ¥377,736,366.55, up from ¥324,217,837.89, reflecting a year-over-year increase of 16.5%[13] - The net profit for Q3 2024 was CNY 65,755,396.60, a decrease of 7.3% compared to CNY 70,794,920.13 in Q3 2023[14] - The total profit for Q3 2024 was CNY 73,438,851.96, down from CNY 77,640,244.84 in the same period last year, reflecting a decline of 5.6%[14] - The operating profit for Q3 2024 was CNY 73,011,117.71, compared to CNY 77,391,011.06 in Q3 2023, indicating a decrease of 5.6%[14] - The total comprehensive income for Q3 2024 was CNY 59,574,196.60, compared to CNY 63,841,070.13 in Q3 2023, representing a decrease of 6.5%[15] - Basic and diluted earnings per share for Q3 2024 were both CNY 0.37, down from CNY 0.40 in Q3 2023, a decline of 7.5%[15] Assets and Liabilities - Total assets as of September 30, 2024, amounted to ¥2,219,488,635.26, reflecting a 2.26% increase from the end of the previous year[2] - The company's total assets increased to ¥2,219,488,635.26, up from ¥2,170,375,592.53, representing a growth of 2.3%[12] - Non-current liabilities totaled ¥29,617,847.04, slightly up from ¥28,413,251.31, reflecting a year-over-year increase of 4.2%[12] - The total equity attributable to shareholders reached ¥2,028,795,493.33, an increase from ¥1,995,956,420.04, marking a growth of 1.6%[12] Cash Flow - The company's cash flow from operating activities showed a decline, with a net amount of ¥42,186,663.06, down 18.83% year-over-year[2] - The cash flow from operating activities for Q3 2024 was CNY 42,186,663.06, down from CNY 51,973,403.92 in Q3 2023, a decline of 18.5%[16] - The cash and cash equivalents decreased by 55% to ¥238,701,954.55, primarily due to the purchase of large-term deposits[5] - The cash and cash equivalents at the end of Q3 2024 were CNY 232,120,388.91, significantly lower than CNY 594,279,468.98 at the end of Q3 2023, a decrease of 60.9%[17] - The net cash flow from investing activities for Q3 2024 was CNY -309,203,548.65, compared to CNY -21,880,759.45 in Q3 2023, indicating a worsening cash outflow situation[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,596, with the largest shareholder, Shen Guofu, holding 24.10% of the shares[8] - The top ten shareholders include individuals with varying ownership percentages, with the second-largest shareholder, Mao Zhilin, holding 4.83%[8] - The company has not disclosed any significant changes in the top ten shareholders due to margin trading activities[8] - The total number of preferred shareholders and their holdings were not applicable for this reporting period[9] Operational Highlights - The company reported a significant increase in accounts receivable, which rose by 217% to ¥3,013,326.29 due to an increase in commercial acceptance bills[5] - Accounts receivable increased from ¥115,202,477.21 to ¥133,923,352.29, representing a growth of about 16.3%[10] - Inventory rose from ¥102,525,211.32 to ¥119,866,096.74, indicating an increase of approximately 16.9%[10] - The total current assets decreased from ¥838,089,609.64 to ¥556,878,580.83, a reduction of about 33.5%[10] - The company reported a credit impairment loss of CNY -750,417.35 in Q3 2024, contrasting with a gain of CNY 1,317,647.03 in Q3 2023[14] Strategic Initiatives - The company plans to expand its market presence and invest in new technologies to drive future growth[12] - The company is focusing on strategic acquisitions to enhance its competitive position in the market[12] - The company participated in the IPO of Zhejiang Fute Technology Co., Ltd., which issued 27.75 million shares at a price of ¥14.00 per share[9] Research and Development - Research and development expenses for the quarter were ¥23,105,891.18, compared to ¥20,783,013.00 in the previous year, indicating a growth of 11.5%[13] Non-Recurring Gains - The company reported a total of ¥879,661.03 in non-recurring gains for the current period, with government subsidies contributing ¥483,598.26[3]

Group 1: Company Overview - The company primarily focuses on two main business sectors: fabric weaving and medical devices [1] - In the fabric sector, the company engages in the R&D, production, and sales of functional fabrics for transportation tools like automobiles [1] - The medical device segment is led by the wholly-owned subsidiary, Weirder, which specializes in the R&D, production, and sales of ultrasound diagnostic and therapeutic equipment [1] Group 2: Management Team - The chairman, Mr. Shen Guofu, is the controlling shareholder and actual controller of the company [1] - The executive team at the parent company consists of professional managers with long tenures, indicating a stable management structure [1] Group 3: Medical Device Development - The medical device sector is one of the company's two key business areas, with a commitment to continuous investment [2] - A new wholly-owned subsidiary was established in Zhejiang, which operates independently and has already achieved certain results [2] - The company is actively developing new products and promoting them in the clinical ultrasound specialty field, focusing on differentiated competition [2] Group 4: Market Strategy - The company aims to expand its product line in ultrasound diagnostic equipment while also developing smart therapeutic devices [2] - Efforts are being made to penetrate the veterinary ultrasound niche market [2]

证券代码：002144 股票简称：宏达高科 公告编号：2024-027 产品名称：彩色多普勒超声系统 规格型号：Z2、Z4、Z6 注册证编号：浙械注准20242061734 注册证批准日期：2024年8月30日 注册证有效期至：2029年8月29日 产品适用范围：适用于人体腹部、浅表器官、神经肌骨、血管、经阴道、 胎儿的超声诊断检查。 宏达高科控股股份有限公司 关于孙公司取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 近期本公司全资孙公司浙江威尔德数智医疗科技有限公司自主研发的数款 彩色多普勒超声系统取得了浙江省药品监督管理局颁发的《医疗器械注册 证》，具体情况如下： 上述医疗器械注册证的取得，说明孙公司浙江威尔德数智医疗科技有限公 司已达成产业化条件，有助于提高公司医疗器械板块的产品竞争力和超声诊断 设备的市场拓展力。所涉及的产品实际销售情况取决于市场的推广效果，请投 资者注意投资风险。 特此公告。 宏达高科控股股份有限公司董事会 二〇二四年九月四日 1 ...

公司目前将对富特科技的股权投资指定为以公允价值计量且其变动计入其 他综合收益的金融资产。除来自富特科技的分红（若有）计入投资收益外，其 公允价值变动将不会产生投资收益，不影响净利润，但会影响归属于上市公司 股东的所有者权益。公司将继续履行信息披露义务，请投资者注意投资风险。 宏达高科控股股份有限公司 关于参股公司股票上市交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司参股的浙江富特科技股份有限公司（下称"富特科技"）人民币普通 股股票已于 2024 年 9 月 4 日在深圳证券交易所上市，证券简称为"富特科技", 证券代码为"301607.SZ"。富特科技目前人民币普通股股份总数为 111,014,571 股，其中 22,368,152 股股票自上市之日起开始上市交易。 公司于 2020 年 10 月公告拟对富特科技进行增资参股，并于同年 12 月完 成入股（详见公司公告 2020-043、2024-045、2020-047）。截至本公告披露日， 公司持有富特科技首次公开发行前股份 3,050,626 股，持股比例为 2.7479%，该 部分 ...

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 275,300,244.25, representing a 10.46% increase compared to CNY 249,239,367.47 in the same period last year[24]. - The net profit attributable to shareholders of the listed company decreased by 12.41% to CNY 42,364,686.99 from CNY 48,364,692.69 year-on-year[24]. - The basic earnings per share decreased by 11.11% to CNY 0.24 from CNY 0.27 in the same period last year[24]. - The company achieved operating revenue of CNY 275.30 million in the first half of 2024, representing a year-on-year increase of 10.46%[36]. - The net profit attributable to shareholders of the listed company was CNY 42.36 million, a decrease of 12.41% year-on-year, while the net profit of the parent company increased by 13.21% to CNY 52.88 million[36]. - The company's main business revenue from fabric weaving reached CNY 192.12 million, up 12.79% year-on-year, contributing to stable growth in revenue and profit[37]. - The total revenue for the first half of 2024 reached CNY 184,282,555.89, representing a year-on-year increase of 11.88%[42]. - The gross profit margin for the fabric weaving segment was 29.07%, with a revenue increase of 11.88% compared to the previous year[43]. - The medical device segment reported a revenue of CNY 26,372,029.78, with a gross profit margin of 52.20%, although revenue decreased by 18.48% year-on-year[43]. - The total comprehensive income for the first half of 2024 was ¥14,676,780.99, significantly lower than ¥51,203,963.69 in the previous year, reflecting a decrease of 71.3%[144]. Cash Flow and Liquidity - The net cash flow from operating activities dropped significantly by 55.49% to CNY 14,723,864.33, compared to CNY 33,081,691.19 in the previous year[24]. - The company reported a significant decrease in cash and cash equivalents, indicating potential liquidity challenges[152]. - The company's cash and cash equivalents decreased to ¥207,892,280.20 from ¥536,148,860.18, representing a decline of approximately 61.3%[134]. - The ending balance of cash and cash equivalents was ¥176,337,886.30, down from ¥342,672,815.75 in the previous period[152]. - Cash flow from operating activities generated a net amount of ¥14,723,864.33, down 55.54% from ¥33,081,691.19 in the same period last year[148]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,159,025,739.65, a decrease of 0.52% from CNY 2,170,375,592.53 at the end of the previous year[24]. - The net assets attributable to shareholders of the listed company decreased by 0.60% to CNY 1,983,991,327.83 from CNY 1,995,956,420.04 at the end of the previous year[24]. - Cash and cash equivalents decreased by 15.07% to ¥207,892,280.20, accounting for 9.63% of total assets[53]. - Accounts receivable increased to ¥139,019,673.87, representing 6.44% of total assets, up from 5.31%[53]. - Total liabilities decreased to ¥123,746,919.30 from ¥137,186,762.36, reflecting a reduction of approximately 9.8%[143]. Research and Development - Research and development expenses increased by 5.48% to CNY 14.10 million, reflecting the company's commitment to innovation[38]. - The company has allocated 1.2 billion yuan for research and development in new technologies and products for the current fiscal year[159]. - Research and development expenses increased to ¥14,100,485.95, compared to ¥13,367,490.43, representing a growth of 5.5%[143]. Market and Industry Risks - The company is exposed to risks related to macroeconomic conditions, downstream market conditions, raw material and product prices, and product quality in the textile industry[5]. - The medical device sector faces increasing competition from multinational companies and domestic enterprises, particularly in the ultrasound diagnostic equipment market[67]. - The company is exposed to raw material price volatility, particularly for nylon, polyester, and various dyes, which could impact production costs[68]. - The international market presents risks due to rising trade protectionism and currency fluctuations, affecting export growth in the knitting and medical device industries[68]. Shareholder Information - The total number of restricted shares increased from 38,862,923 (21.99%) to 40,083,514 (22.68%) due to the addition of 1,220,591 shares[115]. - Chairman Shen Guofu increased his shareholding by 1,305,700 shares, bringing his total to 42,600,090 shares, which is 24.10% of the total shares[115]. - The total number of shareholders at the end of the reporting period was 16,086[120]. Environmental Compliance - The company complies with environmental regulations and has established standards for pollutant emissions, with no reported exceedances in wastewater discharge limits[79]. - The company has a wastewater treatment capacity of 8,000 tons per day, with 4,000 tons discharged and 4,000 tons reused[80]. - The total greenhouse gas emissions for the first half of 2024 amounted to 17,965 tons of CO2, with emissions from fuel combustion at 1,643 tons, purchased electricity at 4,805 tons, and heat generation at 11,517 tons[84]. Corporate Governance - The company has not engaged in any major acquisitions or mergers during the reporting period[97]. - There were no major lawsuits or arbitration matters reported during the period[94]. - The half-year financial report has not been audited[92]. Strategic Outlook - The company plans to expand its market presence through new product launches and technological advancements in the upcoming quarters[159]. - The company aims to achieve a revenue growth target of 10% for the next fiscal year, driven by market expansion and new product offerings[159]. - The company is exploring potential mergers and acquisitions to enhance its market position and product portfolio[159].

证券代码：002144 股票简称：宏达高科 公告编号：2024-024 宏达高科控股股份有限公司 关于公司完成工商变更登记并取得营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 宏达高科控股股份有限公司（以下简称"公司"）分别于2024年4月24日 召开第七届董事会第二十一次会议，2024年5月28日召开2023年年度股东大会， 审议通过了《关于变更公司注册地址并修订<公司章程>的议案》。公司注 册地址由"浙江省海宁市许村镇建设路118号"变更为"浙江省海宁市许村镇大 桥路275号"。具体内容详见公司刊登于巨潮资讯网上（www.cninfo.com.cn） 的相关公告。 一、公司营业执照变更情况 近日，公司已完成了工商变更登记手续，取得了浙江省市场监督管理局 核发的《营业执照》，变更后的企业登记信息如下： 1、名称：宏达高科控股股份有限公司 8、经营范围： 投资管理，资产管理咨询服务，针织及纺织面料、服装、 合成革的制造、加工、销售；印染；房屋租赁，化纤丝、染化料(不含危险品) 的销售。经营进出口业务(详见《进出口企业资格证书》)。(依法须经批准 ...

2023年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 证券代码：002144 股票简称：宏达高科 公告编号：2024-023 宏达高科控股股份有限公司 一、股东大会审议通过权益分派方案情况 1、宏达高科控股股份有限公司(以下简称"公司")2023年年度权益分派 方案已获2024年5月28日召开的公司2023年年度股东大会审议通过，股东大 会决议公告已于2024年5月29日刊登在巨潮资讯网（www.cninfo.com.cn）和 《证券时报》。 2、自权益分派方案披露至实施期间公司股本总额未发生变化。 3、本次实施的权益分派方案与股东大会审议通过的权益分派方案一 致。 4、本次实施权益分派方案距离股东大会审议通过的时间未超过两个 月。 5、本次权益分派方案按固定总额的方式分配，以公司现有总股本 176,762,528股为基数，向全体股东每10股派1.50元人民币现金（含税），分 派总金额为26,514,379.20元。 二、权益分派方案 本公司2023年年度权益分派方案为：以公司现有总股本176,762,528股为 基数，向全体股东每1 ...

证券代码：002144 股票简称：宏达高科 公告编号：2024-022 以上人员任期自本次董事会审议通过之日起至本届董事会进行换届选举之 日止。以上人员简历详见同日披露于证券时报和巨潮资讯网的《第八届董事会第 一次会议决议的公告》。公司董事会审计委员会就公司聘任财务总监和内审 机构负责人的事项进行事前审议，并做出了同意的意见。 | 姓名 | 马强强 | 沈婷婷 | | --- | --- | --- | | 联系地址 | 浙江省海宁市许村镇大桥路 275 号 | 浙江省海宁市许村镇大桥路 275 号 | | 电话 | 0573-87550882 | 0573-87566909 | | 传真 | 0573-87552681 | 0573-87552681 | | 电子信箱 | mqq@zjhongda.com.cn | stt@zjhongda.com.cn | 马强强先生和沈婷婷女士联系方式如下： 特此公告。 宏达高科控股股份有限公司 关于聘任公司高级管理人员、证券事务代表、内审机构负 责人的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为完善公司治理 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 宏达高科控股股份有限公司（以下简称"公司"）于 2024 年 5 月 28 日召开了 2023 年年度股东大会，选举产生了公司第八届董事会。同日下午三点半，公司董事 会在浙江省海宁市许村镇大桥路 275 号公司会议室以现场方式召开了第八届董事会 第一次会议。 本次会议由公司董事沈国甫先生主持，应到董事 9 位，实到董事 9 位，公司监 事、高级管理人员列席了本次会议，会议的召开符合法律、法规、规章及《公司章 程》的规定。 与会董事认真审议，以现场与通讯相结合的表决的方式，作出了如下决议： 1、以 9 票同意、0 票反对、0 票弃权的表决结果审议通过了《关于选举公司第 八届董事会董事长的议案》。 本次董事会选举沈国甫先生为第八届董事会董事长，任期与第八届董事会一致， 即自 2024 年 5 月 28 日至 2027 年 5 月 27 日。 证券代码：002144 股票简称：宏达高科 公告编号：2024-020 宏达高科控股股份有限公司 第八届董事会第一次会议决议公告 2、以 9 票同意、0 票反对、0 票弃权的表决 ...

宏达高科控股股份有限公司 2023 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更前次股东大会决议。 一、会议召开和出席情况 1、宏达高科控股股份有限公司（以下简称"公司"）2023 年年度股东大会于 2024 年 5 月 28 日在浙江省海宁市许村镇大桥路 275 号公司会议室召开。本次会 议由公司董事会召集，由公司董事长沈国甫先生主持。本次会议的召集、召开与 表决程序符合《公司法》、《上市公司股东大会规则》等有关法律、法规、规范性 文件和《公司章程》的规定。 证券代码：002144 股票简称：宏达高科 公告编号：2024-019 2、参加本次股东大会现场会议和网络投票的股东及股东代表共 11 人，代表 的股份总数为 61,841,764 股，占公司有表决权股份总数的 34.99%。其中参与表 决的中小股东及股东代表共计 6 人，代表的股份总数为 8,754,025 股，占公司有 表决权股份总数的 4.95%。 3、为尊重中小投资者利益，提高中小投资者对公 ...